StreetInsider.com News Articles

Form S-3 Aprea Therapeutics, Inc.

Fri, 20 Feb 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260220/26032611.html

Form S-3 Aprea Therapeutics, Inc.

Fri, 20 Feb 2026 06:04:00 -0500

si-local-file:///var/storage/secattach/20260220/26032611.html

Form 8-K Aprea Therapeutics, Inc. For: Feb 18

Wed, 18 Feb 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260218/26018538.html

Form 8-K Aprea Therapeutics, Inc. For: Feb 18

Wed, 18 Feb 2026 08:31:00 -0500

si-local-file:///var/storage/secattach/20260218/26018538.html

Aprea reports second partial response in cancer drug trial

Wed, 18 Feb 2026 08:02:10 -0500

Aprea Therapeutics Inc. (NASDAQ: APRE) reported a second partial response in its Phase 1 trial of WEE1 inhibitor APR-1051 for advanced solid tumors.

The response occurred in a patient with advanced endometrial cancer treated at the 220 mg dose level. The patient achieved a 50% reduction in target lesion measurements and an 87% decline in CA-125 tumor biomarker levels, dropping from 362 U/mL to 47 U/mL. The patient experienced only Grade 1 adverse events and continues treatment.

Both partial responses in the trial occurred in patients with endometrial cancer whose tumors harbor PPP2R1A mutations, at the 150 mg and 220 mg dose

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Wed, 18 Feb 2026 08:00:00 -0500

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level
Patient experienced only Grade 1 adverse events
Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population
Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic index

DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Wed, 18 Feb 2026 08:00:00 -0500

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level
Patient experienced only Grade 1 adverse events
Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population
Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic index

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Tue, 17 Feb 2026 08:00:00 -0500

DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually.

Presentation Details

Date/ time:	February 26, 2026 8:40 am EST
Location:	Virtual
Webcast link:	click here

The webcast will be available

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Tue, 17 Feb 2026 08:00:00 -0500

Presentation Details

Date/ time:	February 26, 2026 8:40 am EST
Location:	Virtual
Webcast link:	click here

The webcast will be available

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 13 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260213/26001763.html

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC

Fri, 13 Feb 2026 17:02:00 -0500

si-local-file:///var/storage/secattach/20260213/26001763.html

Aprea Therapeutics expands patent portfolio for cancer drugs through 2045

Thu, 12 Feb 2026 08:30:48 -0500

Aprea Therapeutics Inc. (NASDAQ: APRE) announced new patent grants in Australia and Japan during 2025 that strengthen intellectual property protection for its DNA damage response cancer therapy programs.

The clinical-stage biopharmaceutical company received patents covering its WEE1 and ATR inhibitor programs, with core patent families expected to provide exclusivity into 2045, according to the company's statement.

Aprea's WEE1 kinase inhibitor program includes one provisional U.S. patent application, two pending U.S. applications, one issued Australian patent granted in 2025, and 13 pending international applications. The core WEE1 patents are expected to provide protection through 2042, excluding regulatory exclusivities.

The company's ATR inhibitor program holds

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Thu, 12 Feb 2026 08:30:00 -0500

New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.

Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated

Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation

DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

Thu, 12 Feb 2026 08:30:00 -0500

New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.

Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated

Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation

Aprea Therapeutics names Eugene Kennedy as chief medical advisor

Wed, 04 Feb 2026 08:32:55 -0500

Aprea Therapeutics Inc. (NASDAQ: APRE) announced the appointment of Eugene Kennedy, MD, as chief medical advisor. The clinical-stage biopharmaceutical company made the appointment following early clinical proof-of-concept results from its ongoing Phase 1 dose-escalation study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors.

Kennedy brings over 20 years of experience in oncology clinical development, regulatory strategy, and senior corporate leadership across biotechnology companies. He currently serves as fractional chief medical officer at Percheron Therapeutics, where he oversees clinical development and regulatory strategy for a Phase 2 immuno-oncology checkpoint inhibitor program.

Previously, Kennedy held chief medical officer positions at Carisma Therapeutics,

Aprea Therapeutics names Eugene Kennedy as chief medical advisor

Wed, 04 Feb 2026 08:32:55 -0500

Previously, Kennedy held chief medical officer positions at Carisma Therapeutics,

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Wed, 04 Feb 2026 08:30:00 -0500

Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051

DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor.

Dr. Kennedy joins Aprea at an important time, following the Company’s recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Wed, 04 Feb 2026 08:30:00 -0500

Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Gilad Oren

Mon, 02 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25930821.html

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Gilad Oren

Mon, 02 Feb 2026 16:08:00 -0500

si-local-file:///var/storage/secattach/20260202/25930821.html

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Hamill John P.

Mon, 02 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260202/25930765.html

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Hamill John P.

Mon, 02 Feb 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260202/25930765.html

Aprea (APRE) PT Lowered to $4 at H.C. Wainwright

Fri, 30 Jan 2026 06:46:11 -0500

H.C. Wainwright analyst Joseph Pantginis lowered the price target on Aprea (NASDAQ: APRE) to $4.00 (from $5.00) while maintaining a Buy rating.

Form 8-K Aprea Therapeutics, Inc. For: Jan 28

Thu, 29 Jan 2026 16:17:00 -0500

si-local-file:///var/storage/secattach/20260129/25916749.html

Form 8-K Aprea Therapeutics, Inc. For: Jan 28

Thu, 29 Jan 2026 16:17:00 -0500

si-local-file:///var/storage/secattach/20260129/25916749.html